Cabenuva® (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension)
for Human Immunodeficiency Virus

Cabenuva is a 2-drug co-packaged product consisting of cabotegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). It is indicated as a complete regimen for treating HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) and have no history of treatment failure or known resistance to cabotegravir or rilpivirine.

Heart
Other top medicines used to treat Human Immunodeficiency Virus - HIV